MEDI-528, now recognized as enokiizumab , represents a groundbreaking treatment targeting the IGF1R, a crucial protein linked in several skin conditions . Early investigation data suggest significant efficacy for the control of moderate to severe eczema , particularly in individuals who have responded poorly to existing remedies. This biological ag